Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Liabilities: 2022-2025

Historic Total Liabilities for Silence Therapeutics (SLN) over the last 2 years, with Sep 2025 value amounting to $72.7 million.

  • Silence Therapeutics' Total Liabilities rose 1968.32% to $72.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.7 million, marking a year-over-year increase of 1968.32%. This contributed to the annual value of $68.6 million for FY2024, which is 29.60% down from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Total Liabilities is $72.7 million, which was up 2.32% from $71.1 million recorded in Q2 2025.
  • Silence Therapeutics' Total Liabilities' 5-year high stood at $97.5 million during Q4 2023, with a 5-year trough of -$40.2 million in Q3 2022.
  • Its 3-year average for Total Liabilities is $54.1 million, with a median of $71.1 million in 2025.
  • Per our database at Business Quant, Silence Therapeutics' Total Liabilities dropped by 29.60% in 2024 and then soared by 17,599.21% in 2025.
  • Silence Therapeutics' Total Liabilities (Quarterly) stood at -$40.2 million in 2022, then reached $97.5 million in 2023, then decreased by 29.60% to $68.6 million in 2024, then surged by 1,968.32% to $72.7 million in 2025.
  • Its Total Liabilities was $72.7 million in Q3 2025, compared to $71.1 million in Q2 2025 and $72.6 million in Q1 2025.